Episurf — Regulatory Filings 2016

Aug 1, 2016

Company Announcement August 1, 2016

Episurf Medical has been granted additional European patent

Episurf Medical has obtained another granted patent in Europe. The patent covers a surgical drilling guide with a functionality for depth adjustments. This guide constitutes a component of Episurf's toolkit for implantation of patient specific joint implants. This is the first patent in this family of patents to be granted.

The generation of new intellectual property and the ongoing maintenance of current IP are key activities which ensures that Episurf's proprietary, existing technologies and future innovations are well protected. The company currently has approximately 80 active patents and patent applications, distributed in 20 patent families.

For more information, please contact:

Rosemary Cunningham Thomas, CEO, Episurf Medical Tel: +46 (0) 70-7655892 Tel: +44 (0) 7803-753603 rosemary@episurf.com

About Episurf Medical

Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and personalized treatment alternatives. Episurf Medical's Episealer® personalized implants and Epiguide® surgical drill guides are developed for treating localized cartilage injury in joints. Episurf Medical's μiFidelity® system enables implants to be cost-efficiently tailored to each individual's unique injury for the optimal fit and minimal intervention. Episurf Medical's head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company's website: www.episurf.com.

This information is information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 12.10 CET on 1 August 2016.